Indications |
Oral Hypertension Adult: Initially, 12.5 mg once daily increased to 25 mg once daily after 2 days. Alternatively, initial dose of 6.25 mg bid increased to 12.5 mg bid after 1-2 wk, increased further if necessary to 50 mg once daily or in divided doses. Elderly: 12.5 mg once daily. Oral Angina pectoris Adult: Initially, 12.5 mg bid increased to 25 mg bid after 2 days. Oral Heart failure Adult: Initially, 3.125 mg bid, doubled to 6.25 mg bid after 2 wk if tolerated, then gradually increased to the max dose the patient can tolerate at intervals of not <2 wk. Max dose: >85 kg: 50 mg bid; <85 kg: 25 mg bid. Oral Left ventricular dysfunction post myocardial infarction Adult: Initially: 6.25 mg bid, if tolerated, after 3-10 days, increase to 12.5 mg bid and then to a target dose of 25 mg bid. |
Contraindications |
Hypersensitivity; severe chronic heart failure, bronchial asthma or related bronchospastic conditions; severe hepatic impairment. Patients with NYHA class IV cardiac failure, 2nd or 3rd ° AV block, sick sinus syndrome (unless a permanent pacemaker is in place), cardiogenic shock or severe bradycardia. Lactation. |
Warnings / Precautions |
Avoid abrupt withdrawal as it may precipitate thyroid storm or exacerbate hyperthyroidism. Liver injury; vascular disease, renal failures, suspected phaeochromocytoma and prinzmetal's variable angina; worsening cardiac failure or fluid retention during increase in dosage of carvedilol; diabetic patients. Pregnancy. |
Adverse Reactions |
Bradycardia, AV block, angina pectoris, hypervolaemia, leucopenia, hypotension, peripheral oedema, allergy, malaise, fluid overload, melena, periodontitis, hyperuricaemia, hyponatraemia, increased alkaline phosphatase, glycosuria, prothrombin time, SGPT and SGOT levels, purpura, somnolence, impotence, albuminuria, hypokinesia, nervousness, sleep disorder, skin reaction, tinnitus, dry mouth, anaemia, sweating, fatigue, arthralgia, aggravation, dizziness. Diarrhoea, nausea, vomiting, insomnia, hypercholesterolaemia, weight gain, abnormal vision, rhinitis, pharyngitis and hypertriglyceridaemia. |
Overdose Reactions |
Symptoms include severe hypotension, bradycardia, cardiac insufficiency, cardiogenic shock and cardiac arrest. Respiratory problems, bronchospasms, vomiting, lapses of consciousness and generalised seizures may also occur. Place the patient in a supine position. Gastric lavage or pharmacologically induced emesis may be used shortly after ingestion. |
Drug Interactions |
Potentiates insulin-induced hypoglycaemic action. Concurrent use with catecholamine-depleting agents and β-receptor blockers may cause marked hypotension. Serum levels may be increased by fluoxetine. May increase serum levels of ciclosporin and digoxin. Potentially Fatal: Rifampin pretreatment results in a decreased Cmax and AUC. Combination with verapamil can lead to severe bradycardia and myocardial depression. See Below for More carvedilol Drug Interactions |
Food Interactions |
Food reduces rate of absorption and risk of hypotension. |
Mechanism of Actions |
Carvedilol causes vasodilation by blocking the activity of α-blockers, mainly at alpha-1 receptors. It exerts antihypertensive effect partly by reducing total peripheral resistance and vasodilation. It is used in patients with renal impairment, NIDDM or IDDM. Absorption: Absorbed well from the GI tract (oral); peak plasma concentrations after 1-2 hr. Distribution: Enters breast milk. Protein-binding: >98%. Metabolism: Hepatic: Considerable first-pass effect. Excretion: Via bile (as metabolites); 6-10 hr (elimination half-life). |
Administration |
Should be taken with food. |
Storage Conditions |
Oral: Store below 30°C. |
ATC Classification |
C07AG02 - carvedilol ; Belongs to the class of alpha and beta blocking agents. Used in the treatment of cardiovascular diseases. |
Storage |
Oral: Store below 30°C. |
Available As |
|
Carvedilol
Post Review about Carvedilol Click here to cancel reply.
Carvedilol Containing Brands
Carvedilol is used in following diseases
Drug - Drug Interactions of Carvedilol
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.